AbbVie staves off another US Humira knockoff to 2023 as European launch looms
Just a few days before Humira knockoffs are set to debut in parts of Europe, AbbVie has settled another round of IP litigation for its ironclad mega-blockbuster franchise in the US.
This time the deal is with Sandoz, Novartis’ generic arm, which has agreed to launch its biosimilar in the US later in 2023 than other competitors will have, per their previous agreements with AbbVie.
Here’s what the succession of launches will look like:
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters